Skip to main content

and
  1. Article

    Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort

    Docetaxel–cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, w...

    Simon Pernot, Emmanuel Mitry, Emmanuelle Samalin, Laetitia Dahan in Gastric Cancer (2014)

  2. No Access

    Chapter

    Traitement des cancers digestifs du sujet âgé

    Les cancers digestifs surviennent dans la grande majorité des cas chez les patients âgés de plus de 65 ans. Compte tenu du vieillissement de la population, l’incidence des cancers digestifs chez les sujets âgé...

    Emmanuel Mitry, Thomas Aparicio, Philippe Rougier in Les cancers digestifs du sujet âgé (2010)

  3. No Access

    Article

    Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment

    Patients with metastatic colorectal cancer (mCRC) who progress despite treatment with fluoropyrimidine and irinotecan or oxaliplatin have diminished survival, but they may derive clinically meaningful benefit ...

    Emmanuel Mitry, Astrid Lièvre in International Journal of Colorectal Disease (2009)

  4. No Access

    Book

    Les cancers digestifs

    Avec la collaboration de l’Association des Gastro-entérologues Oncologues (AGEO)

    Philippe Rougier, Emmanuel Mitry in Oncologie Pratique (2006)